Olson S. C., Ngo-Giang-Huong Nicole, Beck I., Deng W. J., Britto P., Shapiro D. E., Bumgarner R. E., Mullins J. I., Van Dyke R. B., Jourdain Gonzague, Frenkel L. M. (2015). Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission. Aids, 29 (12), p. 1467-1471. ISSN 0269-9370.
Titre du document
Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission
Olson S. C., Ngo-Giang-Huong Nicole, Beck I., Deng W. J., Britto P., Shapiro D. E., Bumgarner R. E., Mullins J. I., Van Dyke R. B., Jourdain Gonzague, Frenkel L. M.
Source
Aids, 2015,
29 (12), p. 1467-1471 ISSN 0269-9370
To prevent mother-to-child-transmission of HIV-1, the 2010 WHO guidelines recommended prenatal zidovudine (ZDV) monotherapy (option A). To determine if ZDV monotherapy selects for HIV resistance in antiretroviral-naive women during pregnancy, specimens from 50 individuals were examined using pyrosequencing. ZDV-resistance mutations were detected at delivery in seven women (14%, 95% confidence interval 6.6-26.5%). These data raise the question whether women administered ZDV monotherapy for prevention of mother-to-child-transmission could have higher risk of virologic failure when later started on combination antiretroviral therapy, as has been demonstrated following single-dose nevirapine prophylaxis.
